CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

What started out as shoulder pain turned into a living nightmare for a Melbourne girl and her family after doctors discovered a large mass in the eight-year-old’s chest, which turned out to be a rare ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.

Emma Operacz was diagnosed with a rare cancer at 21. An unusual treatment and bone marrow donation from her sister saved her ...

After weeks of doctor visits and her condition worsening, Emma Operacz was given an unexpected diagnosis ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...

Immunotherapy uses the power of your immune system to fight your cancer. There are several types of immunotherapies. They include antibody therapies and CAR T-cell therapy. Immunotherapies are among ...

Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with ...